Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger L Nation

Showing results (171-180 of 247) with videos related to

Pageof 25
Sort By:
International Journal of Antimicrobial Agents|October 25, 2016
Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumanniiJustin R Lenhard, Jonathan S Gall, Jurgen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy|September 14, 2011
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic modelPhillip J Bergen, Brian T Tsuji, Jurgen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy|May 6, 2020
Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm ModelHajira Bilal, Phillip J Bergen, Jessica R Tait, et al.
Antimicrobial Agents and Chemotherapy|October 26, 2011
Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-β-1,6-N-acetylglucosamineRebekah Henry, Nuwan Vithanage, Paul Harrison, et al.
Journal of Pharmaceutical Sciences|October 25, 2023
Distinguishing Inducible and Non-Inducible Resistance to Colistin in Pseudomonas aeruginosa by Quantitative and Systems Pharmacology Modeling at Low and Standard InoculaJürgen B Bulitta, Eunjeong Shin, Phillip J Bergen, et al.
Antimicrobial Agents and Chemotherapy|November 9, 2016
Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal ModelCornelia B Landersdorfer, Tri-Hung Nguyen, Linh Thuy Lieu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 27, 2015
Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?Roger L Nation, Samira M Garonzik, Jian Li, et al.
Infectious Diseases and Therapy|December 10, 2015
Optimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaPhillip J Bergen, Zackery P Bulman, Cornelia B Landersdorfer, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2022
Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based ModelingHajira Bilal, Jessica R Tait, Yinzhi Lang, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2017
Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coliNicholas M Smith, Zackery P Bulman, Arthur O Sieron, et al.
Pageof 25

Showing results (171-180 of 247) with videos related to

Sort By:
Pageof 25
International Journal of Antimicrobial Agents|October 25, 2016
Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumanniiJustin R Lenhard, Jonathan S Gall, Jurgen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy|September 14, 2011
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic modelPhillip J Bergen, Brian T Tsuji, Jurgen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy|May 6, 2020
Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm ModelHajira Bilal, Phillip J Bergen, Jessica R Tait, et al.
Antimicrobial Agents and Chemotherapy|October 26, 2011
Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-β-1,6-N-acetylglucosamineRebekah Henry, Nuwan Vithanage, Paul Harrison, et al.
Journal of Pharmaceutical Sciences|October 25, 2023
Distinguishing Inducible and Non-Inducible Resistance to Colistin in Pseudomonas aeruginosa by Quantitative and Systems Pharmacology Modeling at Low and Standard InoculaJürgen B Bulitta, Eunjeong Shin, Phillip J Bergen, et al.
Antimicrobial Agents and Chemotherapy|November 9, 2016
Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal ModelCornelia B Landersdorfer, Tri-Hung Nguyen, Linh Thuy Lieu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 27, 2015
Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?Roger L Nation, Samira M Garonzik, Jian Li, et al.
Infectious Diseases and Therapy|December 10, 2015
Optimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaPhillip J Bergen, Zackery P Bulman, Cornelia B Landersdorfer, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2022
Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based ModelingHajira Bilal, Jessica R Tait, Yinzhi Lang, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2017
Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coliNicholas M Smith, Zackery P Bulman, Arthur O Sieron, et al.
Pageof 25